Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(11):774-775; doi:10.1093/jnci/95.11.774
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Webb, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Webb, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 11, 774-775, June 4, 2003
© 2003 Oxford University Press

NEWS

Work on Breast Cancer Stem Cells Raises Questions About Treatment Strategies

Tracy Webb

The first 10% of the full text of this article appears below.

When a tumor shrinks in size as a result of chemotherapy, it is believed that the patient is responding to treatment. However, tumors often initially shrink in response to treatment only to recur later on, suggesting that tumor shrinkage and patient response may not exactly be synonymous. Why is this?

The answer may lie with cancer stem cells. New data published in April in the Proceedings of the National Academy of Sciences suggest that only a small minority of breast cancer cells—breast cancer stem cells—within a tumor are tumorigenic and thus responsible for driving tumor growth and metastasis. As a result, the bulk of a tumor is actually made up . . . [Full Text of this Article]

Proof of Concept

Not the Controversial Type

New Therapeutic Strategies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?